A Research and Development (R&amp;D) roadmap for influenza vaccines: Looking toward the future

Moore, Kristine A.; Ostrowsky, Julie; Kraigsley, Alison M.; Mehr, Angela J.; Bresee, Joseph S.; Friede, Martin; Gellin, Bruce G.; Golding, Josephine P.; Hart, P. John; Moen, Ann; Weller, Charlotte; Osterholm, Michael T.; Ampofo, William; Barclay, William; Cavaleri, Marco; Cohen, Cheryl; Cowling, Benjamin J.; Cox, Rebecca Jane; Gust, Ian D.; Innis, Bruce L.; Kang, Gagandeep; Katz, Jacqueline M.; Krammer, Florian; Pitisuttithum, Punnee; Post, Diane J.; Rudenko, Larisa; Siqueira, Marilda Mendonça; Weir, Jerry P.

doi:10.1016/j.vaccine.2021.08.010

Cited by 41 publications

(50 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the National Institute of Allergy and Infectious Diseases (NIAID) the criteria for a universal vaccine are: (1) at least 75% efficacy against symptomatic influenza virus infection; (2) protection against Group I and Group II influenza A viruses (influenza B virus would be a secondary target); (3) durable protection that lasts at least 1 year and preferably through multiple seasons; (4) suitable for all age groups [ 98 ]. However, the definition of a universal flu vaccine may vary slightly according to the source [ 99 ]. Potentially, universal vaccines can be created in different ways, namely by rational design of new immunogens that guarantee broad protection or by the introduction of vaccines based on a large number of different antigens.…”

Section: Universal Flu Vaccine Perspectivesmentioning

confidence: 99%

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

et al. 2022

View full text Add to dashboard Cite

The seasonal flu vaccine is, essentially, the only known way to prevent influenza epidemics. However, this approach has limited efficacy due to the high diversity of influenza viruses. Several techniques could potentially overcome this obstacle. A recent first-in-human study of a chimeric hemagglutinin-based universal influenza virus vaccine demonstrated promising results. The coronavirus pandemic triggered the development of fundamentally new vaccine platforms that have demonstrated their effectiveness in humans. Currently, there are around a dozen messenger RNA and self-amplifying RNA flu vaccines in clinical or preclinical trials. However, the applicability of novel approaches for a universal influenza vaccine creation remains unclear. The current review aims to cover the current state of this problem and to suggest future directions for RNA-based flu vaccine development.

show abstract

Section: Universal Flu Vaccine Perspectivesmentioning

confidence: 99%

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The facts clearly show the importance of vaccination for suppressing virus replication. However, the vaccine efficacy is not high enough to suppress the infection in all cases [ 6 , 170 ]. The efficacy of vaccines was greatly biased in certain years [ 170 ] and there are several reasons for this.…”

Section: Current Challenges For Controlling the Pandemic Respiratory Virusesmentioning

confidence: 99%

“…Although vaccination is the cornerstone for controlling seasonal influenza and to achieve the quick containment of an influenza pandemic, the present vaccine strategies are inadequate. Because the efficiency of a vaccine can vary widely, such as from 10% to 60% in the US from 2004 to 2018 [ 6 ], and in Japan, the vaccine efficiency during the 2018–2019 season was less than 50% [ 7 ]. The currently available vaccines are not sufficient to protect the elderly who are at high risk.…”

Section: Introductionmentioning

confidence: 99%

Strategies for fighting pandemic virus infections: Integration of virology and drug delivery

Nakamura

Isoda

Sakoda

et al. 2022

Journal of Controlled Release

View full text Add to dashboard Cite

Respiratory viruses have sometimes resulted in worldwide pandemics, with the influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) being major participants. Long-term efforts have made it possible to control the influenza virus, but seasonal influenza continues to take many lives each year, and a pandemic influenza virus sometimes emerges. Although vaccines for coronavirus disease 2019 (COVID-19) have been developed, we are not yet able to coexist with the SARS-CoV-2. To overcome such viruses, it is necessary to obtain knowledge about international surveillance systems, virology, ecology and to determine that immune responses are effective. The information must then be transferred to drugs. Delivery systems would be expected to contribute to the rational development of drugs. In this review, virologist and drug delivery system (DDS) researchers discuss drug delivery strategies, especially the use of lipid-based nanocarriers, for fighting to respiratory virus infections.

show abstract

“…Several approaches that target conserved regions of the virus such as the hemagglutinin stalk, or stimulate T cell–mediated immune responses, are currently in preclinical development [ 157 , 158 ]. Other strategies to improve vaccine effectiveness include a better understanding and forecasting of viral evolution, the optimization of neuraminidase content, the use of novel adjuvants, and the development of more efficient, nucleic acid–based, vector-based, or recombinant protein–based production platforms [ 158 , 159 ]. Computation- or structure-based design of the hemagglutinin antigens and nanoparticle display are being used to enchance vaccine immunogenicity [ 160 , 161 ].…”

Section: Virus- and Host-targeted Therapies Vaccine Developmentmentioning

confidence: 99%

Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges

et al. 2021

View full text Add to dashboard Cite

The development of safe and effective vaccines in a record time after the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a remarkable achievement, partly based on the experience gained from multiple viral outbreaks in the past decades. However, the Coronavirus Disease 2019 (COVID-19) crisis also revealed weaknesses in the global pandemic response and large gaps that remain in our knowledge of the biology of coronaviruses (CoVs) and influenza viruses, the 2 major respiratory viruses with pandemic potential. Here, we review current knowns and unknowns of influenza viruses and CoVs, and we highlight common research challenges they pose in 3 areas: the mechanisms of viral emergence and adaptation to humans, the physiological and molecular determinants of disease severity, and the development of control strategies. We outline multidisciplinary approaches and technological innovations that need to be harnessed in order to improve preparedeness to the next pandemic.

show abstract

A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future

Cited by 41 publications

References 74 publications

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

Strategies for fighting pandemic virus infections: Integration of virology and drug delivery

Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges

Contact Info

Product

Resources

About